Evidence map›Paper›PMID 35482192›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

A Hybrid Adherent/Suspension Cell-Based Selection Strategy for Discovery of Antibodies Targeting Membrane Proteins.

Patrick J Krohl, Jamie B Spangler

Abstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Patrick J KrohlDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.
Jamie B SpanglerDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA. Jamie.spangler@jhu.edu.

Funding

Cassette exons in neoplastic pro-B-cells: implications for immunotherapyU01CA232563 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI BARASH, YOSEPH, THOMAS-TIKHONENKO, ANDREI · 2018 to 2022
$3.5M
Suprachoroidal nonviral gene transfer of engineered VEGF antagonistsR01EY031097 · NEI · JOHNS HOPKINS UNIVERSITY · PI CAMPOCHIARO, PETER A, GREEN, JORDAN · 2020 to 2023
$2.4M
Immunoengineered nanotechnology for targeted expansion of regulatory T cellsR01EB029455 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI SPANGLER, JAMIE BERTA · 2020 to 2023
$1.7M
Engineered osteogenic growth factors for targeted stimulation of bone regenerationR21DE031436 · NIDCR · JOHNS HOPKINS UNIVERSITY · PI GRAYSON, WARREN L, SPANGLER, JAMIE BERTA · 2022 to 2023
$435k
OPTIMIZING THE PRE-CLINICAL DEVELOPMENT OF IMMUNOTHERAPEUTIC ANTIBODIES THROUGH GLYCOENGINEERINGR21CA249381 · NCI · JOHNS HOPKINS UNIVERSITY · PI SPANGLER, JAMIE BERTA, YAREMA, KEVIN J · 2020 to 2021
$410k
NCI NIH HHS R21 CA249381NCI NIH HHS U01 CA232563NEI NIH HHS R01 EY031097NIBIB NIH HHS R01 EB029455NIDCR NIH HHS R21 DE031436
6 · The paper itself

Abstract

Membrane proteins are favored drug targets and antibody therapeutics represent the fastest-growing category of pharmaceuticals. However, there remains a need for rapid and effective approaches for the discovery of antibodies that recognize membrane proteins to develop a robust clinical pipeline for targeted therapeutics. The challenges associated with recombinant expression of membrane proteins make whole cell screening techniques desirable, as these strategies allow presentation of the target membrane proteins in their native conformations. Here, we describe a workflow that employs both adherent cell-based and suspension cell-based whole cell panning methodologies to enrich for specific binders within a yeast-displayed antibody library. The first round of selection consists of an adherent cell-based approach, wherein a diverse library is panned over target-expressing mammalian cell monolayers in order to debulk the naïve library. Subsequent rounds involve the use of suspension cell-based approaches, facilitated with magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS), to achieve further library enrichment. Finally, we describe a high-throughput approach to screen target binding and specificity of individual clones isolated from selection campaigns.

Indexed as

Membrane ProteinsPeptide LibraryAnimalsAntibodiesFlow CytometryImmunologic TestsMammalsSuspensionsAntibodiesMembrane ProteinsPeptide LibrarySuspensionsAntibody discoveryBiopanningCell panningDirected evolutionMembrane proteinsMolecular engineeringYeast surface display

Identifiers

PMID35482192
PMCPMC9667817

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.